LRG1 Human, Sf9
Leucine Rich Alpha-2-Glycoprotein 1, Leucine-Rich Alpha-2-Glycoprotein, 1300008B03Rik, 2310031E04Rik, HMFT1766, Leucine-rich alpha-2-glycoprotein, LRG1, LRG.
Greater than 95.0% as determined by SDS-PAGE.
Description
LRG1 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 321 amino acids (36-347a.a.) and having a molecular mass of 35.4kDa. LRG1 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
LRG1, a member of the leucine-rich repeat (LRR) protein family, plays a crucial role in various cellular processes, including protein-protein interactions, signal transduction, cell adhesion, and development. Notably, LRG1 expression is observed during the differentiation of granulocytes.
Recombinant LRG1, expressed in Sf9 insect cells using a baculovirus system, is a single, glycosylated polypeptide chain consisting of 321 amino acids (residues 36-347). With a molecular weight of 35.4 kDa, this protein is engineered with a 6-amino acid Histidine tag at the C-terminus to facilitate purification via proprietary chromatographic techniques.
The LRG1 protein solution is provided at a concentration of 0.5 mg/ml and is formulated in Phosphate Buffered Saline (pH 7.4) containing 10% glycerol.
The purity of the LRG1 protein is determined to be greater than 95.0% by SDS-PAGE analysis.
Leucine Rich Alpha-2-Glycoprotein 1, Leucine-Rich Alpha-2-Glycoprotein, 1300008B03Rik, 2310031E04Rik, HMFT1766, Leucine-rich alpha-2-glycoprotein, LRG1, LRG.
ADPVTLSPKD CQVFRSDHGS SISCQPPAEI PGYLPADTVH LAVEFFNLTH LPANLLQGAS KLQELHLSSN GLESLSPEFL RPVPQLRVLD LTRNALTGLP PGLFQASATL DTLVLKENQL EVLEVSWLHG LKALGHLDLS GNRLRKLPPG LLANFTLLRT LDLGENQLET LPPDLLRGPL QLERLHLEGN KLQVLGKDLL LPQPDLRYLF LNGNKLARVA AGAFQGLRQL DMLDLSNNSL ASVPEGLWAS LGQPNWDMRD GFDISGNPWI CDQNLSDLYR WLQAQKDKMF SQNDTRCAGP EAVKGQTLLA VAKSQHHHHH H
Product Science Overview
LRG1 is a secreted glycoprotein that is abundantly present in the microenvironment of many tumors, where it contributes to vascular dysfunction . The recombinant form of LRG1, produced in Sf9 Baculovirus cells, is a single, glycosylated polypeptide chain containing 321 amino acids and has a molecular mass of 35.4 kDa . This recombinant protein is expressed with a 6-amino acid His tag at the C-terminus and is purified using proprietary chromatographic techniques .
LRG1 plays a significant role in various physiological and pathological processes. It is constitutively expressed by hepatocytes and neutrophils, and its expression is induced in response to various inflammatory stimuli . LRG1 has been implicated in multiple human conditions, including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders .
One of the key functions of LRG1 is its involvement in the TGFβ signaling pathway, where it acts as an upstream modifier . This pathway is crucial for regulating cell growth, differentiation, and immune responses. LRG1’s modulation of TGFβ signaling can lead to various effects on different cell types, including epithelial, immune, mesenchymal, and cancer cells .
LRG1 has been identified as a pathogenic factor in several diseases. It disrupts the cellular interactions required for the formation and maintenance of mature blood vessels, contributing to a highly hypoxic and immunosuppressive microenvironment . This vasculopathic role of LRG1 makes it a potential therapeutic target for diseases characterized by abnormal vascular function.
In cancer, LRG1 is present abundantly in the tumor microenvironment, where it impedes the delivery of therapeutics by contributing to vascular dysfunction . The development of antibody-drug conjugates (ADCs) targeting LRG1 has shown promise in improving the efficacy of cancer treatments .
Given its role in disease pathogenesis, LRG1 is being explored as a therapeutic target. Inhibition of LRG1 through gene deletion or function-blocking antibodies has been shown to attenuate disease progression in animal studies . This suggests that targeting LRG1 could be a viable strategy for treating various diseases, including cancer and inflammatory disorders.
